Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159507 | 0.91 | CCR1 (0.64) | CCR1NR1I2 | |
| SCHEMBL2159258 | 0.89 | CCR1 (0.71) | CCR1 | |
| SCHEMBL1603622 | 0.87 | CCR1 (0.84) | CCR1 | |
| SCHEMBL2160056 | 0.86 | CCR1 (0.49) | CCR1NR1I2 | |
| SCHEMBL1603449 | 0.86 | CCR1 (0.71) | CCR1 | |
| SCHEMBL12397978 | 0.82 | CCR1 (0.79) | CCR1NR1I2 | |
| SCHEMBL2159665 | 0.82 | CCR1 (0.44) | CCR1NR1I2 | |
| SCHEMBL2159453 | 0.82 | CCR1 (0.54) | CCR1NR1I2 | |
| SCHEMBL2159451 | 0.82 | CCR1 (0.54) | CCR1NR1I2 | |
| SCHEMBL10297206 | 0.82 | CCR1 (0.80) | CCR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633226-B2 | Piperidinyl derivative as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130023564-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR7, CCR1, CCR2 | CCR1 2/4885NR1I2 425/4885 |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | CCR1 1/4885NR1I2 101/4885 |
| US-20130023564-A1 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCL11 | CCR1 5/4885NR1I2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.